Sionna Therapeutics plans to cut its workforce by approximately 46% and expects about $6.4 million in restructuring and related charges. The move is intended to concentrate resources on SION-451 and SION-2222, extend cash runway into the second half of 2029 and support a Phase 2a trial expected to begin in the first quarter of 2027.
Key Highlights
- Employee severance and related post-employment benefits account for approximately $5.3 million of the restructuring estimate.
- Sionna will wind down vendor arrangements linked to the SION-719 add-on program.
- Stock Options with exercise prices above $18.00 will be repriced for eligible employees who remain after the workforce reduction.
Sionna Therapeutics, Inc. (NASDAQ: SION) plans to reduce its workforce by approximately 46% and expects about $6.4 million in restructuring and related charges.
Sionna Sets Restructuring Charges and Leadership Changes
Caroline Stark Beer’s employment as chief Business officer ends without cause on September 15, 2026, subject to the terms of her severance plan. Charlotte McKee, Elena Ridloff and Jennifer Fitzpatrick will assume added research and development, business, and program management responsibilities, respectively, with no compensation changes.
Option Repricing
Options under the 2025 Plan with exercise prices above $18.00, along with certain options priced at $18.00, will be reset to the common stock’s closing price on September 17, 2026, for eligible employees who remain after the reduction. The repriced awards will revert to their original exercise prices if exercised before the retention period ends; that period ends upon the earliest of specified events. Sionna expects the dual combination Phase 2a proof-of-concept trial to begin in the first quarter of 2027.
FAQs
Q: What are Sionna Therapeutics’ restructuring costs?
A: Sionna currently estimates aggregate restructuring and related charges of approximately $6.4 million. The estimate includes severance, SION-719 contract close-out costs and stock-based compensation expense.
Q: How will Sionna’s workforce reduction affect its executives?
A: Several executives will take on expanded responsibilities in connection with the restructuring. Charlotte McKee, Elena Ridloff and Jennifer Fitzpatrick will add research, business and program management roles.
Q: What is Sionna Therapeutics’ stock option repricing plan?
A: Eligible employees will receive repriced options when existing exercise prices exceed $18.00 or meet specified conditions at $18.00. The new exercise price will match the common stock’s closing price on September 17, 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.